rFVIII‐Fc in severe haemophilia A: The incentive switch in case of high risk of joint bleedings
Sign Up to like & getrecommendations! Published in 2022 at "European Journal of Clinical Investigation"
DOI: 10.1111/eci.13824
Abstract: Efmoroctocog alfa, the first recombinant factor VIII fusion protein with extended half‐life (rFVIII‐Fc), has been hypothesized to lower FVIII consumption in patients with severe Haemophilia A (pwSHA), without reducing clinical efficacy. What about real life? read more here.
Keywords: haemophilia incentive; incentive switch; switch case; severe haemophilia ... See more keywords